-
Je něco špatně v tomto záznamu ?
Rheohaemapheresis in the treatment of nonvascular age-related macular degeneration
M. Blaha, E. Rencova, H. Langrova, J. Studnicka, V. Blaha, P. Rozsival, M. Lanska, L. Sobotka,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem
- MeSH
- biologické markery krev MeSH
- časové faktory MeSH
- elektroretinografie MeSH
- lidé MeSH
- lipoproteiny krev MeSH
- makulární degenerace krev diagnóza patofyziologie terapie MeSH
- noční vidění MeSH
- obnova funkce MeSH
- optická koherentní tomografie MeSH
- prediktivní hodnota testů MeSH
- progrese nemoci MeSH
- reologie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- separace krevních složek metody MeSH
- viskozita krve MeSH
- výsledek terapie MeSH
- zraková ostrost MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- Geografické názvy
- Česká republika MeSH
PURPOSE: To evaluate the experience with rheohaemapheresis (RH) in the treatment of age-related macular degeneration (AMD). METHODS: Thirty-eight patients were each treated with 8 procedures of RH (14 males, 24 females). The control group consisted of 34 random patients (30 females, 4 males) with the dry form of AMD but not treated by RH. Our modification of the cascade method (named rheohaemapheresis) was used for plasma separation. After plasma separation (blood cell separator, Cobe Spectra, Denver, CO, USA), the separated plasma was pumped through a rheofilter (Evaflux 4A, Kuraray, Osaka, Japan) to remove lipoproteins and other high-molecular-weight rheologic factors. RESULTS: In treated patients, best-corrected visual acuity (BCVA) increased significantly from 0.61 (0.06-1.00) to 0.68 (0.35-1.00) after 2.5 years (p = 0.035). We found no significant changes or differences in scotopic activity, whereas cone response and paramacular activity in the more peripheral region between 14° and 22° of eccentricity were significantly higher in treated patients after 2.5 years. CONCLUSION: RH therapy favourably influenced BCVA. During 2.5 years after the therapy, no progression of dry to wet AMD was observed in our patients. RH reduced the area of drusenoid retinal pigment epithelium detachment (which increased during the natural course of dry form AMD). RH influenced rheological markers and probably improved metabolism in the affected retinal areas which lead to the aforementioned positive results.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13031671
- 003
- CZ-PrNML
- 005
- 20131003095911.0
- 007
- ta
- 008
- 131002s2013 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.atherosclerosissup.2012.10.023 $2 doi
- 035 __
- $a (PubMed)23357162
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Blaha, M $u 2nd Department of Internal Medicine, Separator Center, Charles University, Medical Faculty and Teaching Hospital, 50009 Hradec Kralove, Czech Republic. blaham@email.cz
- 245 10
- $a Rheohaemapheresis in the treatment of nonvascular age-related macular degeneration / $c M. Blaha, E. Rencova, H. Langrova, J. Studnicka, V. Blaha, P. Rozsival, M. Lanska, L. Sobotka,
- 520 9_
- $a PURPOSE: To evaluate the experience with rheohaemapheresis (RH) in the treatment of age-related macular degeneration (AMD). METHODS: Thirty-eight patients were each treated with 8 procedures of RH (14 males, 24 females). The control group consisted of 34 random patients (30 females, 4 males) with the dry form of AMD but not treated by RH. Our modification of the cascade method (named rheohaemapheresis) was used for plasma separation. After plasma separation (blood cell separator, Cobe Spectra, Denver, CO, USA), the separated plasma was pumped through a rheofilter (Evaflux 4A, Kuraray, Osaka, Japan) to remove lipoproteins and other high-molecular-weight rheologic factors. RESULTS: In treated patients, best-corrected visual acuity (BCVA) increased significantly from 0.61 (0.06-1.00) to 0.68 (0.35-1.00) after 2.5 years (p = 0.035). We found no significant changes or differences in scotopic activity, whereas cone response and paramacular activity in the more peripheral region between 14° and 22° of eccentricity were significantly higher in treated patients after 2.5 years. CONCLUSION: RH therapy favourably influenced BCVA. During 2.5 years after the therapy, no progression of dry to wet AMD was observed in our patients. RH reduced the area of drusenoid retinal pigment epithelium detachment (which increased during the natural course of dry form AMD). RH influenced rheological markers and probably improved metabolism in the affected retinal areas which lead to the aforementioned positive results.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a separace krevních složek $x metody $7 D001781
- 650 _2
- $a viskozita krve $7 D001809
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a elektroretinografie $7 D004596
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lipoproteiny $x krev $7 D008074
- 650 _2
- $a makulární degenerace $x krev $x diagnóza $x patofyziologie $x terapie $7 D008268
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a noční vidění $7 D055254
- 650 _2
- $a prediktivní hodnota testů $7 D011237
- 650 _2
- $a obnova funkce $7 D020127
- 650 _2
- $a reologie $7 D012212
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a optická koherentní tomografie $7 D041623
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a zraková ostrost $7 D014792
- 651 _2
- $a Česká republika $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Rencova, E $u -
- 700 1_
- $a Langrova, H $u -
- 700 1_
- $a Studnicka, J $u -
- 700 1_
- $a Blaha, V $u -
- 700 1_
- $a Rozsival, P $u -
- 700 1_
- $a Lanska, M $u -
- 700 1_
- $a Sobotka, L $u -
- 773 0_
- $w MED00006853 $t Atherosclerosis. Supplements $x 1878-5050 $g Roč. 14, č. 1 (2013), s. 179-84
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23357162 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20131002 $b ABA008
- 991 __
- $a 20131003100429 $b ABA008
- 999 __
- $a ok $b bmc $g 995758 $s 830116
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 14 $c 1 $d 179-84 $i 1878-5050 $m Atherosclerosis supplements $n Atheroscler Suppl $x MED00006853
- LZP __
- $a Pubmed-20131002